AAAAAA

   
Results: 1-25 | 26-40
Results: 1-25/40
SAFETY AND COST-EFFECTIVENESS OF A 10 X 10(9) L TRIGGER FOR PROPHYLACTIC PLATELET TRANSFUSIONS COMPARED WITH THE TRADITIONAL 20 X 10(9)/L TRIGGER - A PROSPECTIVE COMPARATIVE TRIAL IN 105 PATIENTS WITH ACUTE MYELOID-LEUKEMIA/
Authors: WANDT H FRANK M EHNINGER G SCHNEIDER C BRACK N DAOUD A FACKLERSCHWALBE I FISCHER J GACKLE R GEER T HARMS P LOFFLER B OHL S OTREMBA B RAAB M SCHONROCKNABULSI P STROBEL G WINTER R LINK H
Citation: H. Wandt et al., SAFETY AND COST-EFFECTIVENESS OF A 10 X 10(9) L TRIGGER FOR PROPHYLACTIC PLATELET TRANSFUSIONS COMPARED WITH THE TRADITIONAL 20 X 10(9)/L TRIGGER - A PROSPECTIVE COMPARATIVE TRIAL IN 105 PATIENTS WITH ACUTE MYELOID-LEUKEMIA/, Blood, 91(10), 1998, pp. 3601-3606
LOW MORBIDITY AND NO MORTALITY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA AND MITOXANTRONE PLUS AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL SUPPORT FOR HIGH-RISK BREAST-CANCER PATIENTS
Authors: KROGER N KRUGER WH GIESEKING F JAENICKE F SCHULTZE W FUSS H MOBUS V KONIGSMANN M BERDEL WE SCHAFERECKERT K WANDT H METZNER B ILLIGER HJ FRICKHOFEN N WULF G WORMANN B KOLBE K HOSSFELD DK MAAS H JONAT W ZANDER AR
Citation: N. Kroger et al., LOW MORBIDITY AND NO MORTALITY OF HIGH-DOSE CYCLOPHOSPHAMIDE, THIOTEPA AND MITOXANTRONE PLUS AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL SUPPORT FOR HIGH-RISK BREAST-CANCER PATIENTS, European journal of cancer, 34, 1998, pp. 92-92
PRESTIMULATION OF CD34(++) CD90(+) PROGENITOR CELLS WITH THROMBOPOIETIN (TPO) ALONE ALLOWS BOTH MEGAKARYOCYTIC AND ERYTHROID-DIFFERENTIATION, WHEREAS PRESTIMULATION WITH TPO+EPO OR WITH TPO+EPO+SCF PROMOTES PREDOMINANTLY ERYTHROPOIESIS/
Authors: BIRKMANN J SIEVERT T SMETAK M WANDT H GALLMEIER WM
Citation: J. Birkmann et al., PRESTIMULATION OF CD34(++) CD90(+) PROGENITOR CELLS WITH THROMBOPOIETIN (TPO) ALONE ALLOWS BOTH MEGAKARYOCYTIC AND ERYTHROID-DIFFERENTIATION, WHEREAS PRESTIMULATION WITH TPO+EPO OR WITH TPO+EPO+SCF PROMOTES PREDOMINANTLY ERYTHROPOIESIS/, Experimental hematology, 26(8), 1998, pp. 190-190
EXPERIENCES IN SEQUENTIAL HIGH-DOSE CHEMOTHERAPY (HDCT) SUPPORTED BY G-CSF MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IN ADVANCED OVARIAN-CANCER
Authors: WANDT H BIRKMANN J SCHAEFERECKART K DENZEL T BOTH A EGGER H GALLMEIER WM
Citation: H. Wandt et al., EXPERIENCES IN SEQUENTIAL HIGH-DOSE CHEMOTHERAPY (HDCT) SUPPORTED BY G-CSF MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IN ADVANCED OVARIAN-CANCER, Bone marrow transplantation, 22, 1998, pp. 14-14
CYCLOPHOSPHAMIDE THIOTEPA/MITOXANTRONE WITH AUTOLOGOUS STEM-CELL RESCUE FOR HIGH-RISK STAGE-II AND STAGE-III BREAST-CANCER/
Authors: KRUGER WH KROGER N KONIGMANN M BERDEL WE FUSS H SCHULTZE W GIESEKING F SCHAFERECKART K MOBUS V FRICKHOFEN N WANDT H ILLIGER HJ METZNER B KOLBE K WORMANN B TRUMPER L HUBER C MAASS H JONAT W ZANDER AR
Citation: Wh. Kruger et al., CYCLOPHOSPHAMIDE THIOTEPA/MITOXANTRONE WITH AUTOLOGOUS STEM-CELL RESCUE FOR HIGH-RISK STAGE-II AND STAGE-III BREAST-CANCER/, Bone marrow transplantation, 22, 1998, pp. 31-31
BMT IN REFRACTORY OR RELAPSED ADULT ALL PATIENTS TREATED IN THE GERMAN MULTICENTER ALL STUDIES
Authors: ARNOLD R BUNJES D DEEG HJ EINSELE H FAUSER AA FINKE J HERTENSTEIN B HEYLL A KOLB HJ KOLBE K MARTIN H NIEDERWIESER D SCHAEFER UW SCHMITZ N SCHWERDTFEGER R SIEGERT W WANDT H ZANDER A GOEKBUGET N HOELZER D
Citation: R. Arnold et al., BMT IN REFRACTORY OR RELAPSED ADULT ALL PATIENTS TREATED IN THE GERMAN MULTICENTER ALL STUDIES, Bone marrow transplantation, 21, 1998, pp. 2-2
LOW TOXICITY OF HIGH-DOSE CTM FOLLOWED BY AUTOLOGOUS STEM-CELL REINFUSION FOR HIGH-RISK BREAST-CANCER
Authors: KRUGER WH KROGER N KOLBE K HUBER C GIESEKING F JANICKE F KONIGSMANN M BERDEL WE KERSCHGENS C MAYR AC SCHAFERECKERT K WANDT H SCHULTZE W FUSS H METZNER B ILLIGER HJ FRICKHOFEN N MOBUS V HOSSFELD DK JONAT W ZANDER AR
Citation: Wh. Kruger et al., LOW TOXICITY OF HIGH-DOSE CTM FOLLOWED BY AUTOLOGOUS STEM-CELL REINFUSION FOR HIGH-RISK BREAST-CANCER, Bone marrow transplantation, 21, 1998, pp. 221-221
G-CSF STARTED ON DAY-MYELOABLATIVE CHEMOTHERAPY (CT) WITH STEM-CELL SUPPORT, BUT NOT AFTER MYELOABLATIVE REGIMENS WITH AUTOLOGOUS STEM-CELLTRANSPLANTATION (ASCT)(1 SHORTENS THE DURATION OF LEUKOCYTOPENIA AFTER SEQUENTIAL NON)
Authors: WANDT H SCHAFER K GOTTLER B BIRKMANN J GALLMEIER WM
Citation: H. Wandt et al., G-CSF STARTED ON DAY-MYELOABLATIVE CHEMOTHERAPY (CT) WITH STEM-CELL SUPPORT, BUT NOT AFTER MYELOABLATIVE REGIMENS WITH AUTOLOGOUS STEM-CELLTRANSPLANTATION (ASCT)(1 SHORTENS THE DURATION OF LEUKOCYTOPENIA AFTER SEQUENTIAL NON), Bone marrow transplantation, 21, 1998, pp. 362-362
THE ABSOLUTE NUMBER OF CIRCULATING CD34+ CELLS TIGHTLY CORRELATES WITH THE NUMBER OF HEMATOPOIETIC PROGENITOR CELLS IN THE APHERESIS PRODUCT NOT ONLY FOR THE DAY OF MONITORING BUT ALSO FOR THE FOLLOWING DAY
Authors: BIRKMANN J SCHAFER K WANDT H GALLMEIER WM
Citation: J. Birkmann et al., THE ABSOLUTE NUMBER OF CIRCULATING CD34+ CELLS TIGHTLY CORRELATES WITH THE NUMBER OF HEMATOPOIETIC PROGENITOR CELLS IN THE APHERESIS PRODUCT NOT ONLY FOR THE DAY OF MONITORING BUT ALSO FOR THE FOLLOWING DAY, Bone marrow transplantation, 21, 1998, pp. 677-677
G-CSF STARTED ON DAY-MYELOABLATIVE CHEMOTHERAPY (CT) WITH STEM-CELL SUPPORT, BUT NOT AFTER MYELOABLATIVE REGIMENS WITH AUTOLOGOUS STEM-CELLTRANSPLANTATION (ASCT)(1 SHORTENS THE DURATION OF LEUKOCYTOPENIA AFTER SEQUENTIAL NON)
Authors: WANDT H SCHAFER K GOTTLER B BIRKMANN J GALLMEIER WM
Citation: H. Wandt et al., G-CSF STARTED ON DAY-MYELOABLATIVE CHEMOTHERAPY (CT) WITH STEM-CELL SUPPORT, BUT NOT AFTER MYELOABLATIVE REGIMENS WITH AUTOLOGOUS STEM-CELLTRANSPLANTATION (ASCT)(1 SHORTENS THE DURATION OF LEUKOCYTOPENIA AFTER SEQUENTIAL NON), Bone marrow transplantation, 21, 1998, pp. 808-808
TUMOR-CELL CONTAMINATION OF PERIPHERAL-BLOOD STEM-CELL HARVESTS IN PATIENTS WITH ADVANCED OVARIAN-CANCER DETECTED BY IMMUNOCYTOCHEMISTRY
Authors: WANDT H SCHLIMOK G BIRKMANN J SCHAFER K GALLMEIER WM
Citation: H. Wandt et al., TUMOR-CELL CONTAMINATION OF PERIPHERAL-BLOOD STEM-CELL HARVESTS IN PATIENTS WITH ADVANCED OVARIAN-CANCER DETECTED BY IMMUNOCYTOCHEMISTRY, Bone marrow transplantation, 21, 1998, pp. 809-809
COEXPRESSION OF MYELOID, ERYTHROID, MEGA-KARYOCYTIC, LYMPHOID AND EARLY MARKERS ON MOBILIZED CD34+ PROGENITOR CELLS
Authors: BIRKMANN J SMETAK M WANDT H SCHAFERECKART K SIEVERT T GALLMEIER WM
Citation: J. Birkmann et al., COEXPRESSION OF MYELOID, ERYTHROID, MEGA-KARYOCYTIC, LYMPHOID AND EARLY MARKERS ON MOBILIZED CD34+ PROGENITOR CELLS, Bone marrow transplantation, 21, 1998, pp. 828-828
CORRELATION OF CYTOGENETIC, MOLECULAR CYTOGENETIC, AND CLINICAL FINDINGS IN 59 PATIENTS WITH ANLL OR MDS AND ABNORMALITIES OF THE SHORT ARMOF CHROMOSOME-12
Authors: STREUBEL B SAUERLAND C HEIL G FREUND M BARTELS H LENGFELDER E WANDT H LUDWIG WD NOWOTNY H BALDUS M GROTHAUSPINKE B BUCHNER T FONATSCH C
Citation: B. Streubel et al., CORRELATION OF CYTOGENETIC, MOLECULAR CYTOGENETIC, AND CLINICAL FINDINGS IN 59 PATIENTS WITH ANLL OR MDS AND ABNORMALITIES OF THE SHORT ARMOF CHROMOSOME-12, British Journal of Haematology, 100(3), 1998, pp. 521-533
THE TRANSPLANTATION OF HEMATOPOIETIC STEM-CELLS .2.
Authors: LINK H KOLB HJ EBELL W HOSSFELD DK ZANDER A NIETHAMMER D WANDT H GROSSEWILDE H SCHAEFER UW
Citation: H. Link et al., THE TRANSPLANTATION OF HEMATOPOIETIC STEM-CELLS .2., Medizinische Klinik, 92(9), 1997, pp. 534-545
THE TRANSPLANTATION OF HEMATOPOIETIC STEM -CELLS .1.
Authors: LINK H KOLB HJ EBELL W HOSSFELD DK ZANDER A NIETHAMMER D WANDT H GROSSEWILDE H SCHAEFER UW
Citation: H. Link et al., THE TRANSPLANTATION OF HEMATOPOIETIC STEM -CELLS .1., Medizinische Klinik, 92(8), 1997, pp. 480
G-CSF (LENOGRASTIM) AFTER CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA - APLACEBO-CONTROLLED RANDOMIZED TRIAL
Authors: LINK H WANDT H SCHONROCKNABULSI P EHNINGER G FRANKE A GACKLE R GEER T STROBEL G LINKESCH W KRIEGER O NIEDERWIESER D NIKIFORAKIS E OHL S OTREMBA B PITTERMANN E SCHMIDT H TISCHLER J WEISS J WILHELM M BADRI N
Citation: H. Link et al., G-CSF (LENOGRASTIM) AFTER CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA - APLACEBO-CONTROLLED RANDOMIZED TRIAL, Experimental hematology, 25(8), 1997, pp. 35-35
SUCCESSFUL TREATMENT OF IFOSMAIDE-ASSOCIA TED CNS DISORDERS WITH METHYLENE-BLUE
Authors: DEMANDT M WANDT H
Citation: M. Demandt et H. Wandt, SUCCESSFUL TREATMENT OF IFOSMAIDE-ASSOCIA TED CNS DISORDERS WITH METHYLENE-BLUE, Deutsche Medizinische Wochenschrift, 121(17), 1996, pp. 575-575
51 PATIENTS WITH ACUTE MYELOID-LEUKEMIA AND TRANSLOCATION T(8-21)(Q22-Q22) - AN ADDITIONAL DELETION IN 9Q IS AN ADVERSE PROGNOSTIC FACTOR
Authors: SCHOCH C HAASE D HAFERLACH T GUDAT H BUCHNER T FREUND M LINK H LENGFELDER E WANDT H SAUERLAND MC LOFFLER H FONATSCH C
Citation: C. Schoch et al., 51 PATIENTS WITH ACUTE MYELOID-LEUKEMIA AND TRANSLOCATION T(8-21)(Q22-Q22) - AN ADDITIONAL DELETION IN 9Q IS AN ADVERSE PROGNOSTIC FACTOR, Leukemia, 10(8), 1996, pp. 1288-1295
TOPOISOMERASE-II ACTIVITIES IN AML BLASTS AND THEIR CORRELATION WITH CELLULAR-SENSITIVITY TO ANTHRACYCLINES AND EPIPODOPHYLLOTOXINES
Authors: GIESELER F GLASMACHER A KAMPFE D WANDT H NUESSLER V VALSAMAS S KUNZE J WILMS K
Citation: F. Gieseler et al., TOPOISOMERASE-II ACTIVITIES IN AML BLASTS AND THEIR CORRELATION WITH CELLULAR-SENSITIVITY TO ANTHRACYCLINES AND EPIPODOPHYLLOTOXINES, Leukemia, 10(7), 1996, pp. 1177-1180
TOPOISOMERASE-II ACTIVITIES IN AML BLASTS AND THEIR CORRELATION WITH CELLULAR-SENSITIVITY TO ANTHRACYCLINES AND EPIPODOPHYLLOTOXINES
Authors: GIESELER F GLASMACHER A KAMPFE D WANDT H NUESSLER V VALSAMAS S KUNZE J WILMS K
Citation: F. Gieseler et al., TOPOISOMERASE-II ACTIVITIES IN AML BLASTS AND THEIR CORRELATION WITH CELLULAR-SENSITIVITY TO ANTHRACYCLINES AND EPIPODOPHYLLOTOXINES, Leukemia, 10, 1996, pp. 46-49
INTENSIVE POSTREMISSION THERAPY IN ACUTE MYELOID-LEUKEMIA - RESULTS OF A PROSPECTIVE COMPARATIVE TRIAL
Authors: HUBNER G LINK H SCHONROCKNABULSI P WANDT H GRAMATZKI M LOFFLER B FACKLERSCHWALBE I QUEISSER W BRACK N GEER T RAAB M OHL S SCHNEIDER B SCHNEIDER C FREUND M POLIWODA H EHNINGER G
Citation: G. Hubner et al., INTENSIVE POSTREMISSION THERAPY IN ACUTE MYELOID-LEUKEMIA - RESULTS OF A PROSPECTIVE COMPARATIVE TRIAL, Medizinische Klinik, 91, 1996, pp. 26-32
THE 10.000 MU-L TRIGGER COMPARED TO 20.000/MU-L FOR PROPHYLACTIC PLATELET TRANSFUSION IN AML - A PROSPECTIVE COMPARATIVE MULTICENTER STUDY/
Authors: WANDT H FRANK M SCHNEIDER C EHNINGER G LINK H
Citation: H. Wandt et al., THE 10.000 MU-L TRIGGER COMPARED TO 20.000/MU-L FOR PROPHYLACTIC PLATELET TRANSFUSION IN AML - A PROSPECTIVE COMPARATIVE MULTICENTER STUDY/, Blood, 88(10), 1996, pp. 1760-1760
IN AML IMMUNOPHENOTYPING IS IMPORTANT FOR DIAGNOSIS AND PROGNOSIS
Authors: GRAMATZKI M REPP R DIEHL S STROBEL G WANDT H LOFFLER B BODENSTEIN H SCHONROCK P SCHLIMOK G HEIDEMANN E OTREMBA B OHL S SCHNEIDER C EHNINGER G LINK H
Citation: M. Gramatzki et al., IN AML IMMUNOPHENOTYPING IS IMPORTANT FOR DIAGNOSIS AND PROGNOSIS, Blood, 88(10), 1996, pp. 2230-2230
TOPO-II ACTIVITIES CORRELATE WITH CELLULAR-SENSITIVITY TO ANTHRACYCLINES AND EPIPODO-PHYLLOTOXINES IN AML
Authors: GIESELER F GLASMACHER A WANDT H CLARK M
Citation: F. Gieseler et al., TOPO-II ACTIVITIES CORRELATE WITH CELLULAR-SENSITIVITY TO ANTHRACYCLINES AND EPIPODO-PHYLLOTOXINES IN AML, Blood, 88(10), 1996, pp. 2247-2247
RESULTS OF BMT IN HIGH-RISK ADULT ALL PATIENTS TREATED IN THE GERMAN MULTICENTER ALL STUDIES
Authors: ARNOLD R BUNJES D EINSELE H FAUSER A FINKE J GRAMATZKI M HAAS R HEYLL A KOLB HJ KOLBE K LINK H MARTIN H SCHAEFER UW SCHUMACHER G SCHMITZ N SIEGERT W WANDT H ZANDER AR MESSERER D HOELZER D
Citation: R. Arnold et al., RESULTS OF BMT IN HIGH-RISK ADULT ALL PATIENTS TREATED IN THE GERMAN MULTICENTER ALL STUDIES, Blood, 88(10), 1996, pp. 2446-2446
Risultati: 1-25 | 26-40